false 0001335105 0001335105 2024-12-19 2024-12-19 0001335105 LIXT:CommonStockParValue0.0001PerShareMember 2024-12-19 2024-12-19 0001335105 LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember 2024-12-19 2024-12-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): December 19, 2024

 

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

delaware   001-39717   20-2903526

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

 

680 East Colorado Boulevard, Suite 180

Pasadena, California 91101

(Address of principal executive offices)

 

(631) 830-7092

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share  

 

LIXT

  

 

The Nasdaq Stock Market LLC

Warrants to Purchase Common Stock, par value $0.0001 per share  

 

LIXTW

  

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On December 19, 2024, the Company held its Annual Meeting . The matters voted upon were:

 

Proposal 1: The election of five director nominees to the Company’s Board of Directors to serve for a one-year term expiring at the 2025 annual meeting of stockholders.

 

Proposal 2: To ratify the appointment of Weinberg & Company, P.A. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

 

Proposal 3: To approve, on an advisory basis, the compensation of the Company’s named executive officers.

 

The results of the voting were as follows:

 

Proposal 1 (election of directors):

 

Each of the director nominees to the Company’s Board of Directors was elected as follows:

 

Nominee  Votes For  Votes Withheld  Broker Non-Votes
Dr. Stephen Forman  653,305  80,078  670,623
Dr. Yun Yen  691,844  41,615  670,547
Regina Brown  691,346  42,113  670,547
Dr. René Bernards  691,863  41,596  670,547
Bas van der Baan  678,222  55,161  670,623

 

Proposal 2 (appointment of accounting firm):

 

Votes For  Votes Against  Abstain  Broker Non-Votes
1,329,980  56,472  17,554  0

 

Proposal 3 (compensation of officers):

 

Votes For  Votes Against  Abstain  Broker Non-Votes
672,202  40,248  21,009  670,547

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 20, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC.
  (Registrant)
     
  By: /s/ BASTIAAN VAN DER BAAN
    Bastiaan van der Baan
    Chief Executive Officer

 

3

v3.24.4
Cover
Dec. 19, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 19, 2024
Entity File Number 001-39717
Entity Registrant Name LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Entity Central Index Key 0001335105
Entity Tax Identification Number 20-2903526
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 680 East Colorado Boulevard
Entity Address, Address Line Two Suite 180
Entity Address, City or Town Pasadena
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91101
City Area Code (631)
Local Phone Number 830-7092
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock, par value $0.0001 per share  
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol LIXT
Security Exchange Name NASDAQ
Warrants to Purchase Common Stock, par value $0.0001 per share  
Title of 12(b) Security Warrants to Purchase Common Stock, par value $0.0001 per share
Trading Symbol LIXTW
Security Exchange Name NASDAQ
Lixte Biotechnology (NASDAQ:LIXTW)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Lixte Biotechnology 차트를 더 보려면 여기를 클릭.
Lixte Biotechnology (NASDAQ:LIXTW)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Lixte Biotechnology 차트를 더 보려면 여기를 클릭.